Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation treatments for overactive bladder using Uroplasty's Urgent PC Neuromodulation System.
[More]
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.
[More]
Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.
[More]
Thousands of women suffer from overactive bladder (OAB) or the sudden need to urinate, yet many don't get relief from medication. Researchers at Loyola University Health System believe certain bacteria may be to blame.
[More]
TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has dosed the first patient in its second Phase 2 clinical study with LiRIS, its novel product candidate, in patients with Interstitial Cystitis.
[More]
A recent study conducted by a group of German scientists revealed the presence of a previously unknown cell in the urethra of mice. These chemosensory cholinergic brush cells are in close contact to sensory neurons that express cholinergic receptors.
[More]
Today, the National Association for Continence (NAFC) announced findings from a new, nationwide survey of women about overactive bladder (OAB).
[More]
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
[More]
Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.
[More]
The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.
[More]
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.
[More]
If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.
[More]
Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
[More]
The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.
[More]
Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.
[More]
The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.
[More]
Implantation of tension-free vaginal transobturator tape is a highly effective and long lasting treatment for women with stress urinary incontinence.
[More]
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare.
[More]
Mirabegron, a β3-adrenoreceptor agonist, has shown 12-month safety, tolerability, and persistence of effect in patients with overactive bladders, show study findings.
[More]
The National Association For Continence (NAFC) is hosting free educational events during National Bladder Health Week. Bladder Health Week occurs every year during the second full week in November. This year Bladder Health Week will be held from November 12 - 16.
[More]